Olaparib on a gap schedule with chemotherapy does not improve responses vs chemotherapy alone in the neoadjuvant setting for patients with BRCA wild-type TNBC.
Shahrzad A. Zamani discusses the research on cancer disparities in patients within the LGBTQI+ population, and how these findings could inform further research and decisions in clinical practice.